FI893805A - Fettsyrakomposition. - Google Patents

Fettsyrakomposition. Download PDF

Info

Publication number
FI893805A
FI893805A FI893805A FI893805A FI893805A FI 893805 A FI893805 A FI 893805A FI 893805 A FI893805 A FI 893805A FI 893805 A FI893805 A FI 893805A FI 893805 A FI893805 A FI 893805A
Authority
FI
Finland
Prior art keywords
weight
fatty acids
fettsyrakomposition
acid
epa
Prior art date
Application number
FI893805A
Other languages
English (en)
Other versions
FI893805A0 (fi
Inventor
Harald Breivik
Bernt Boerretzen
Knut Helkaos Dahl
Hans Einar Krokan
Kaare H Boenaa
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10641979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI893805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of FI893805A0 publication Critical patent/FI893805A0/fi
Publication of FI893805A publication Critical patent/FI893805A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
FI893805A 1988-08-11 1989-08-11 Fettsyrakomposition. FI893805A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888819110A GB8819110D0 (en) 1988-08-11 1988-08-11 Antihypertensive drug & method for production

Publications (2)

Publication Number Publication Date
FI893805A0 FI893805A0 (fi) 1989-08-11
FI893805A true FI893805A (fi) 1990-02-12

Family

ID=10641979

Family Applications (1)

Application Number Title Priority Date Filing Date
FI893805A FI893805A (fi) 1988-08-11 1989-08-11 Fettsyrakomposition.

Country Status (24)

Country Link
US (3) US5502077A (fi)
JP (1) JP2810916B2 (fi)
KR (1) KR0126286B1 (fi)
AT (1) AT398779B (fi)
AU (1) AU616784B2 (fi)
BE (1) BE1002547A5 (fi)
CA (1) CA1337548C (fi)
CH (1) CH680789A5 (fi)
DE (1) DE3926658C2 (fi)
DK (1) DK173371B1 (fi)
ES (1) ES2018384A6 (fi)
FI (1) FI893805A (fi)
FR (1) FR2635263A1 (fi)
GB (2) GB8819110D0 (fi)
GR (1) GR1000567B (fi)
HK (1) HK84196A (fi)
IE (1) IE64524B1 (fi)
IL (1) IL91275A (fi)
IT (1) IT1235879B (fi)
LU (1) LU87570A1 (fi)
NL (1) NL193459C (fi)
NZ (1) NZ230022A (fi)
SE (1) SE504742C2 (fi)
ZA (1) ZA895512B (fi)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
DK198991D0 (da) * 1991-12-10 1991-12-10 Simanol A S Fiskeprodukt
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
JPH08512336A (ja) * 1993-04-29 1996-12-24 ノルスク・ヒドロ・アクシェセルスカープ 脂肪酸およびその誘導体のクロマトグラフィーによる分画方法
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
WO1995009622A1 (en) * 1993-10-06 1995-04-13 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
IT1264987B1 (it) * 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
GB9404483D0 (en) * 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
CA2236089C (en) * 1995-11-24 2002-03-05 Loders-Croklaan B.V. Composition based on fish oil
US5866150A (en) * 1996-03-20 1999-02-02 Aquaculture Technology Incorporated Antibacterially active extracts from the marine algae chaetoceros and methods of use
EP1004303B1 (en) * 1997-06-16 2004-10-13 Nippon Suisan Kaisha, Ltd. Composition having capability of removing risk factor during exercise
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
EP1025190A2 (en) * 1997-10-23 2000-08-09 The Procter & Gamble Company Fatty acids, soaps, surfactant systems, and consumer products based thereon
NO309795B1 (no) * 1998-07-01 2001-04-02 Norsk Hydro As FremgangsmOte for O stabilisere oljer samt anvendelse derav, fremgangsmOte for O stabilisere pigmenter, og fremgangsmOte for fremstilling av for
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
US7112609B2 (en) * 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6998501B1 (en) 1999-08-30 2006-02-14 Ocean Nutrition Canada Limited Nutritional supplement for lowering serum triglyceride and cholesterol levels
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
WO2001051598A1 (en) 2000-01-11 2001-07-19 Monsanto Technology Llc Process for making an enriched mixture of polyunsaturated fatty acid esters
ES2298197T3 (es) * 2000-01-31 2008-05-16 Harting S.A. Composiciones que contienen esteres de acidos grasos de fitosterol y de policosanol para reducir el colesterol y los trigliceridos de la sangre.
US6890894B2 (en) * 2000-02-22 2005-05-10 The Procter & Gamble Company Fatty acids, soaps surfactant systems, and consumer products based thereon
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
DE60022987T2 (de) * 2000-05-22 2006-10-19 Pro Aparts - Investimentos E Consultoria Lda., Funchal Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
NZ518504A (en) * 2002-04-22 2005-05-27 Ind Res Ltd Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
AU2003240187A1 (en) * 2002-06-17 2003-12-31 Medestea Research And Production S.R.L. A process for preparing long chain saturated or unsaturated oxygenated compounds
EP2295529B2 (en) * 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
US7279018B2 (en) 2002-09-06 2007-10-09 Fortum Oyj Fuel composition for a diesel engine
US7041840B2 (en) * 2002-12-18 2006-05-09 Alberta Research Council Inc. Antioxidant triacylglycerols and lipid compositions
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
DE10261061A1 (de) * 2002-12-24 2004-07-15 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
US20040235948A1 (en) * 2003-03-05 2004-11-25 Solvay Pharmaceuticals Gmbh Treatment of diabetic patients with omega-3-fatty acids
DE10317109A1 (de) * 2003-04-14 2004-11-11 Cognis Deutschland Gmbh & Co. Kg Zubereitungen zur oralen Aufnahme
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
JP2008516890A (ja) * 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
EP1656935A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for the treatment of pruritus
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
BRPI0607569A2 (pt) * 2005-03-08 2009-09-15 Reliant Pharmaceuticals Inc composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
CN102050720B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
WO2006123550A1 (ja) * 2005-05-16 2006-11-23 Nippon Suisan Kaisha, Ltd. 炎症性疾患予防又は治療剤
US20060292217A1 (en) * 2005-06-03 2006-12-28 Schmidt Robbin D Nutritional supplement and soft gelatin capsule delivery system
WO2007016256A2 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
DE102005040463A1 (de) 2005-08-26 2007-03-01 Cognis Ip Management Gmbh Verwendung von Gemischen aus Polyphenolen und physiologisch aktiven ungesättigten Fettstoffen
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
DE102005054577A1 (de) 2005-11-16 2007-05-24 Cognis Ip Management Gmbh Verwendung von Estern ungesättigter, physiologisch aktiver Fettsäuren als Nährmedien für Zellkulturen
CA2625640A1 (en) * 2005-12-09 2007-06-21 Drugtech Corporation Intravenous essential fatty acid emulsion
EP2364701A1 (en) * 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
EP1991196B1 (en) 2006-03-03 2016-10-12 Fmc Corporation Method and apparatus for the preparation of capsules.
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007103557A2 (en) 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
WO2007142118A1 (ja) 2006-05-31 2007-12-13 Mochida Pharmaceutical Co., Ltd. 多重リスク患者の心血管イベント発症予防用組成物
WO2008011178A2 (en) * 2006-07-21 2008-01-24 Reliant Pharmaceuticals, Inc. Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
JP2010506920A (ja) * 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
RU2509071C2 (ru) 2006-11-01 2014-03-10 Пронова Биофарма Норге Ас Новые липидные соединения
EP2094640A4 (en) * 2006-11-01 2015-05-20 Pronova Biopharma Norge As ALPHA-SUBSTITUTED OMEGA-3 LIPIDS WHICH ARE ACTIVATORS OR MODULATORS OF THE PEROXISOMPROLIPATOR ACTOR-ACTIVATED RECEPTOR (PPAR)
BRPI0717972A2 (pt) * 2006-11-01 2013-11-12 Pronova Biopharma Norge As Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
WO2008132552A2 (en) * 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
CA2667153A1 (en) * 2006-11-03 2008-11-20 Pronova Biopharma Norge As Fatty acid alcohols
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20100130611A1 (en) * 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1967197A1 (en) * 2007-03-09 2008-09-10 Cognis IP Management GmbH Use of preparations, purifications and extracts of aloe
NZ582576A (en) 2007-06-29 2012-05-25 Takeda Pharmaceutical Seamless capsule comprising gelatin and a plasticizer
AU2008269989B2 (en) * 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids
WO2009009040A2 (en) * 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
US20100267828A1 (en) * 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009070589A1 (en) * 2007-11-30 2009-06-04 Jbs United, Inc. Method and composition for treating pulmonary hemorrhage
US8575409B2 (en) 2007-12-20 2013-11-05 Syntroleum Corporation Method for the removal of phosphorus
MY157189A (en) 2008-01-10 2016-05-13 Takeda Pharmaceutical Capsule formulation
US20090182049A1 (en) * 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
MX2010012482A (es) 2008-05-15 2010-12-01 Pronova Biopharma Norge As Proceso para aceite de kril.
US8581013B2 (en) 2008-06-04 2013-11-12 Syntroleum Corporation Biorenewable naphtha composition and methods of making same
US20090300971A1 (en) 2008-06-04 2009-12-10 Ramin Abhari Biorenewable naphtha
MX2011001419A (es) 2008-08-07 2011-05-25 Prodotti Antibiotici Spa Tratamiento a largo plazo de deficiencia cardiaca sintomatica.
PT2334295T (pt) * 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US20100130608A1 (en) * 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
US8231804B2 (en) 2008-12-10 2012-07-31 Syntroleum Corporation Even carbon number paraffin composition and method of manufacturing same
US8563792B2 (en) * 2008-12-16 2013-10-22 Cetane Energy, Llc Systems and methods of generating renewable diesel
EP2384192B1 (en) 2009-01-05 2017-10-25 Calanus AS Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease
SI2596786T1 (sl) 2009-02-10 2020-03-31 Amarin Pharmaceuticals Ireland Limited, Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
ES2894340T3 (es) 2009-03-09 2022-02-14 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
KR101759353B1 (ko) * 2009-04-17 2017-07-18 나타크 파마 에스.엘 오메가-3 지방산이 풍부하고 피탄산 함량이 적은 조성물
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK3278665T3 (da) 2009-04-29 2020-11-30 Amarin Pharmaceuticals Ie Ltd Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9101942B2 (en) 2009-06-16 2015-08-11 Aurora Algae, Inc. Clarification of suspensions
US20110033595A1 (en) * 2009-08-10 2011-02-10 Rudolf Krumbholz Fatty acid fractionation process, fatty acid products and use thereof
US20110033531A1 (en) * 2009-08-10 2011-02-10 Dracopharma, Inc. Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
JP5696149B2 (ja) * 2009-09-10 2015-04-08 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ シームレスなアルギン酸塩カプセル
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2011041710A2 (en) * 2009-10-01 2011-04-07 Martek Biosciences Corporation Docosahexaenoic acid gel caps
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
US9370493B2 (en) * 2009-10-23 2016-06-21 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
EP3865469A3 (en) * 2009-12-30 2021-11-17 BASF Pharma (Callanish) Limited Polyunsaturated fatty acid compositions obtainable by a simulated moving bed chromatographic separation process
AU2013204090B2 (en) * 2009-12-30 2015-01-29 Basf Pharma (Callanish) Limited Simulated moving bed chromatographic separation process
US20110178105A1 (en) * 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
CA3043081C (en) * 2010-03-04 2020-02-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US8394900B2 (en) 2010-03-18 2013-03-12 Syntroleum Corporation Profitable method for carbon capture and storage
EP2568826A4 (en) 2010-05-13 2014-03-26 Nitromega Corp NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
EP2593141B1 (en) * 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20140017308A1 (en) * 2010-09-08 2014-01-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
US20140004186A1 (en) * 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CL2010001587A1 (es) * 2010-12-27 2013-01-11 Golden Omega S A Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2776544A1 (en) 2011-11-09 2014-09-17 Evonik Membrane Extraction Technology Limited Membrane-based processes for reducing at least one impurity and making a concentrate comprising at least one natural component from a non-marine fatty acid oil mixture, and compositions resulting thereof
KR101466617B1 (ko) 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
AU2013201793B2 (en) * 2012-01-06 2015-03-19 Chrysalis Pharma Ag DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20150004224A1 (en) 2012-01-06 2015-01-01 Omthera Phrmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
DK3072510T3 (da) 2012-03-30 2019-08-12 Micelle Biopharma Inc Omega-3-fedtsyreestersammensætninger
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
LT2659881T (lt) 2012-04-30 2018-02-12 Tillotts Pharma Ag Uždelsto atpalaidavimo vaisto forma
AR095182A1 (es) * 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
US9540306B2 (en) * 2012-05-14 2017-01-10 Nippon Suisan Kaisha, Ltd. Highly unsaturated fatty acid or highly unsaturated fatty acid ethyl ester with reduced environmental pollutants, and method for producing same
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
EP2897595B1 (en) 2012-09-24 2020-06-03 Aker Biomarine Antarctic As Omega -3 compositions
WO2014060847A1 (en) 2012-09-24 2014-04-24 Aker Biopharma As Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
US20150258050A1 (en) * 2012-10-23 2015-09-17 Deakin University Method for reducing triglycerides
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
KR20150103009A (ko) * 2012-12-06 2015-09-09 마티나스 바이오파마, 인코포레이티드 도코사펜타에노산을 포함하는 조성물의 투여
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20150374660A1 (en) * 2013-02-26 2015-12-31 Jiva Pharma, Inc. Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses
US9328303B2 (en) 2013-03-13 2016-05-03 Reg Synthetic Fuels, Llc Reducing pressure drop buildup in bio-oil hydroprocessing reactors
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9266973B2 (en) 2013-03-15 2016-02-23 Aurora Algae, Inc. Systems and methods for utilizing and recovering chitosan to process biological material
US20140275596A1 (en) * 2013-03-15 2014-09-18 Aurora Algae, Inc. Algal omega 7 and algal omega 3 blend compositions
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US8969259B2 (en) 2013-04-05 2015-03-03 Reg Synthetic Fuels, Llc Bio-based synthetic fluids
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3542791A1 (en) 2013-10-29 2019-09-25 Tillotts Pharma AG A delayed release drug formulation
US9895332B2 (en) * 2013-10-30 2018-02-20 Patheon Softgels, Inc. Enteric soft capsules comprising polyunsaturated fatty acids
EP3066183A4 (en) * 2013-11-08 2017-09-27 Omega Protein Corporation Purification of dpa enriched oil
EP3118186B1 (fr) 2013-12-11 2022-02-09 Novasep Process Installation chromatographique de production d acides gras polyinsatures
BR112016015718B1 (pt) 2014-01-07 2021-12-07 Novasep Process Solutions Processo de purificação de aminoácidos aromáticos
TWI725937B (zh) 2014-06-06 2021-05-01 美商海洋原料公司 ω-３組成物、劑型及使用方法
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
TWI532482B (zh) * 2014-09-01 2016-05-11 國立中山大學 阿魏酸用以製備提升血紅蛋白釋放氧氣至人體內各器官及周邊組織能力之藥物的用途
JP6816012B2 (ja) 2015-03-26 2021-01-20 ティベリオ ブリュジーズ 多価不飽和脂肪酸の精製方法
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3219209A1 (de) 2016-03-19 2017-09-20 DMK Deutsches Milchkontor GmbH Lagerstabile milchzubereitung enthaltend ascorbinsäure
ES2902006T3 (es) 2016-06-27 2022-03-24 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos médicos
IT201700054543A1 (it) 2017-05-19 2018-11-19 Gleaner Srls Preparato come fonte di Omega-3
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2019241563A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3750536A1 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158541A (en) * 1959-12-18 1964-11-24 Escambia Chem Corp Product for reduction of blood cholesterol concentration
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
GB2033745B (en) * 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
AU527784B2 (en) * 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
GB1604554A (en) * 1978-05-26 1981-12-09 Dyerberg J Pharmaceutical and food formulations
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
JPS59172416A (ja) * 1983-03-18 1984-09-29 Terumo Corp 脂肪輸液
GB2140806B (en) * 1983-05-28 1987-10-28 Sekimoto Hiroshi Stabilisation of unsaturated fatty acids, fish oils or fish
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS60133094A (ja) * 1983-12-21 1985-07-16 日清製油株式会社 高純度エイコサペンタエン酸の製造法
AU4595985A (en) * 1984-08-10 1986-02-13 Sentrachem Limited Cancer treatment
US4675132A (en) * 1985-03-28 1987-06-23 The United States Of America As Represented By The Secretary Of Commerce Polyunsaturated fatty acids from fish oils
GB8524276D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
NO157302C (no) * 1985-12-19 1988-02-24 Norsk Hydro As Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
JPS6388159A (ja) * 1986-09-30 1988-04-19 Nippon Oil & Fats Co Ltd ドコサヘキサエン酸エステルの製造法
AU601238B2 (en) * 1986-11-13 1990-09-06 Efamol Holdings Plc A method of treatment of pregnancy induced hypertension
DE3643848A1 (de) * 1986-12-22 1988-09-01 Natec Inst Naturwiss Verfahren zur herstellung hochraffinierter essbarer glyceridoele mit einem anteil an ungesaettigten fettsaeuren im triglyceridverband und ihre verwendung
GB8705459D0 (en) * 1987-03-09 1987-04-15 Efamol Ltd Treatment of peptic ulcers
HU202088B (en) * 1987-03-18 1991-02-28 Caola Kozmetikai Method for producing dietetic preparation
HU203660B (en) * 1987-04-23 1991-09-30 Biogal Gyogyszergyar Improved process for producing food-additive composition rich in omega-3-unsaturated fatty acids
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses

Also Published As

Publication number Publication date
KR900002771A (ko) 1990-03-23
JP2810916B2 (ja) 1998-10-15
SE504742C2 (sv) 1997-04-14
GR890100507A (en) 1990-08-22
GB2221843A (en) 1990-02-21
IE64524B1 (en) 1995-08-09
NL8902020A (nl) 1990-03-01
AU616784B2 (en) 1991-11-07
BE1002547A5 (fr) 1991-03-19
GB8917711D0 (en) 1989-09-20
GB8819110D0 (en) 1988-09-14
JPH02104522A (ja) 1990-04-17
AU3896789A (en) 1990-02-15
FI893805A0 (fi) 1989-08-11
ES2018384A6 (es) 1991-04-01
NL193459B (nl) 1999-07-01
SE8902701L (sv) 1990-02-12
LU87570A1 (fr) 1990-01-08
NZ230022A (en) 1990-10-26
HK84196A (en) 1996-05-24
FR2635263A1 (en) 1990-02-16
FR2635263B1 (fi) 1992-02-14
CA1337548C (en) 1995-11-14
GB2221843B (en) 1992-12-02
NL193459C (nl) 1999-11-02
AT398779B (de) 1995-01-25
US5656667A (en) 1997-08-12
GR1000567B (el) 1992-08-26
DK392089D0 (da) 1989-08-10
US5502077A (en) 1996-03-26
IT1235879B (it) 1992-11-23
ZA895512B (en) 1990-07-25
DK173371B1 (da) 2000-09-04
IL91275A0 (en) 1990-03-19
IT8921521A0 (it) 1989-08-11
DE3926658A1 (de) 1990-02-15
DE3926658C2 (de) 1998-10-15
DK392089A (da) 1990-02-12
CH680789A5 (fi) 1992-11-13
SE8902701D0 (sv) 1989-08-09
KR0126286B1 (ko) 1997-12-26
IL91275A (en) 1996-01-19
US5698594A (en) 1997-12-16
IE892317L (en) 1990-02-11
ATA191889A (de) 1994-06-15

Similar Documents

Publication Publication Date Title
FI893805A (fi) Fettsyrakomposition.
IL55227A (en) Pharmaceutical compositions comprising(all-z)-5,8,11,14,17-eicosapentaenoic acid or its salts,esters or amides for the treatment and prophylaxis of thromboembolic conditions
ATE96313T1 (de) Fettsaeure-zusammensetzungen.
IL87488A0 (en) Pharmaceutical compositions for the topical treatment of conditions associated with photodamaged skin,comprising substituted propenyl phenyl derivatives
DE3875286T2 (de) Essentielle fettsaeure enthaltende zusammensetzungen.
TW336171B (en) Pharmaceutical composition for use in the treatment of vulvar dystrophy and/or vaginal dryness
MA22818A1 (fr) Procede de preparation de compositions polyhydroxyamide d'acide gras .
ATE258792T1 (de) Diät mit hohem lipidgehalt
SE8901041D0 (sv) Antitrombotiska farmaceutiska preparat samt foerfarande foer deras framstaellning
AU558002B2 (en) Enhancement of 1 series pg production using retinol or carotenoids and linolenic acid
ATE22532T1 (de) Pharmazeutische zusammensetzung.
AU560756B2 (en) Composition containing an essential fatty acid and brotin

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: NORSK HYDRO A.S.